Aethlon Medical, Inc.

Equities

AEMD

US00808Y4061

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:30:00 2024-04-26 pm EDT 5-day change 1st Jan Change
1.36 USD -9.51% Intraday chart for Aethlon Medical, Inc. -6.85% -37.90%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Aethlon Medical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Transcript : Aethlon Medical, Inc., Q3 2024 Earnings Call, Feb 14, 2024
Transcript : Aethlon Medical, Inc., Q2 2024 Earnings Call, Nov 14, 2023
Aethlon Medical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Aethlon Medical, Inc Announces Executive Changes CI
Aethlon Medical, Inc. Announces Appointment Ofguy Ciprian as Chief Operating Officer CI
HC Wainwright Adjusts Price Target on Aethlon Medical to $23 From $90, Maintains Buy Rating MT
Aethlon Medical, Inc. Receives Clearance from Drug Controller General of India for Potential Phase 1 Trial of its Hemopurifier(R) in Oncology CI
Aethlon Medical Board Approves 1-for-10 Reverse Stock Split MT
Transcript : Aethlon Medical, Inc., Q1 2024 Earnings Call, Aug 10, 2023
Aethlon Medical, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Aethlon Medical, Inc. Appoints Nicolas Gikakis as Member of the Board and Member of the Nominating Committee CI
Transcript : Aethlon Medical, Inc., Q4 2023 Earnings Call, Jun 28, 2023
Aethlon Medical, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Transcript : Aethlon Medical, Inc., Q3 2023 Earnings Call, Feb 13, 2023
Aethlon Medical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Aethlon Medical Taps Namsa to Manage Planned Clinical Trial of Medical Device for Cancer MT
North American Morning Briefing : Stock Futures -2- DJ
Maxim Downgrades Aethlon Medical to Hold From Buy MT
Transcript : Aethlon Medical, Inc., Q2 2023 Earnings Call, Nov 14, 2022
Aethlon Medical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Aethlon Medical, Inc. Announces Early Feasibility Study of the Hemopurifier CI
Transcript : Aethlon Medical, Inc. - Shareholder/Analyst Call
Aethlon Medical, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Transcript : Aethlon Medical, Inc., Q1 2023 Earnings Call, Aug 09, 2022
Chart Aethlon Medical, Inc.
More charts
Aethlon Medical, Inc. (Aethlon) is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections suppression, seed the spread of metastasis and inhibit the benefit of cancer therapies. The Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression. Hemopurifier helps to bind and clear multiple different glycosylated viruses, such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), Dengue, West Nile, multiple strains of influenza, Ebola, Chikungunya, smallpox, monkeypox, multiple herpes viruses, a MERS-CoV related pseudovirus, and others. Hemopurifier is used as a device for two independent indications: the treatment of individuals with advanced or metastatic cancer and the treatment of life threating viruses that are not approved therapies.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.36 USD
Average target price
25.05 USD
Spread / Average Target
+1,741.91%
Consensus
  1. Stock Market
  2. Equities
  3. AEMD Stock
  4. News Aethlon Medical, Inc.
  5. Aethlon Medical Board Approves 1-for-10 Reverse Stock Split